BUSINESS

301 Employees Apply for Shionogi’s Voluntary Buyout Program

November 1, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Shionogi said on October 31 that a total of 301 employees raised their hands for a voluntary redundancy program announced in July. The applicants left the company on the same day. The program, which ran from August 1 through September…

To read the full story

Shionogi Workforce Down 341 after Voluntary Buyout Program
June 24, 2024
Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023

BUSINESS

CSL Behring Japan President Yoshida to Step Down
June 8, 2026
Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
June 8, 2026
Takeda Swings to Loss after Booking Amitiza Litigation Charge
June 8, 2026
GNI to Acquire Ayumi Pharma in 44.8 Billion Yen Deal
June 8, 2026
Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…